Prescription Medications for Dry Eye Disease
Dry eye disease is more than simply not making enough tears. A healthy tear film depends on three things: producing enough natural tears, controlling inflammation, and preventing tears from evaporating too quickly. When this balance is disrupted, the eye’s surface can become dry, irritated, and inflamed. Inflammation can then make tear production and tear quality even worse. Because dry eye can have different causes, treatment is tailored to the problems affecting each patient rather than relying only on artificial tears.
Medications that reduce inflammation and help restore tear production
XIIDRA® (lifitegrast 5%) reduces inflammation through a targeted pathway. It blocks the interaction between two proteins, LFA-1 and ICAM-1, helping reduce the activity of immune cells and the inflammatory signals linked to dry eye disease.
Xiidra may begin improving symptoms relatively quickly. In clinical studies, some patients noticed less dryness and discomfort as early as 2 weeks, with further improvement over time. Because dry eye is often a chronic inflammatory condition, regular use is important—even after symptoms begin to improve.
VEVYE® (cyclosporine 0.1%) reduces inflammation caused by T cells, a type of immune cell involved in dry eye disease. By calming inflammation on the eye’s surface and around the tear glands, Vevye may help these tissues function more normally and improve the eye’s ability to produce and maintain tears.
CEQUA® (cyclosporine 0.09%) also reduces inflammation associated with dry eye disease and helps support the tear-producing system. Its nanomicellar formulation is designed to help deliver cyclosporine to the eye’s surface.
RESTASIS® (cyclosporine 0.05%) reduces inflammation on the eye’s surface and around the tear glands. With continued use, Restasis may help increase natural tear production and improve tear-film stability.
For some patients, an ophthalmologist may prescribe a short course of a topical corticosteroid, such as loteprednol, to quickly reduce inflammation on the eye’s surface. EYSUVIS® (loteprednol etabonate 0.25%) is specifically approved for short-term treatment of dry-eye signs and symptoms and may be helpful during periods when symptoms suddenly worsen.
Medications that improve natural tear production
TRYPTYR® (acoltremon) takes a newer approach to dry eye treatment. It activates TRPM8 sensory receptors on the eye’s surface, sending signals through the trigeminal nerve pathway that can increase the eye’s natural, baseline tear production.
TYRVAYA® (varenicline nasal spray) activates receptors in the nasal trigeminal pathway. This stimulates the natural connection between the nerves, tear glands, and eye’s surface, helping increase tear production. Because Tyrvaya is used as a nasal spray rather than an eye drop, it does not need to be placed directly on an already-sensitive eye.
Medication that reduces tear evaporation
MIEBO® (perfluorohexyloctane) treats another important cause of dry eye: tears evaporating too quickly. Many patients—especially those with meibomian gland dysfunction—produce tears but lose them rapidly because the protective oil layer of the tear film is not working properly. Miebo is a water-free medication that forms a layer at the surface of the tear film and helps reduce evaporation.
Treating the Cause, Not Just the Symptoms
No single dry eye medication is right for every patient. Some eyes need better control of inflammation, some need more natural tear production, and others need protection from excessive evaporation. Many patients have more than one of these problems and may benefit from a combination of treatments.
A careful examination of the tear film, eyelids, meibomian glands, and eye’s surface helps identify the main causes of dry eye. This allows us to create an individualized treatment plan focused on restoring a healthier, more stable tear film.
Which Dry Eye Medication Does What?
Dry eye disease is not the same in every patient. Some people do not produce enough natural tears, some have significant inflammation, and others produce tears that evaporate too quickly. Many patients have a combination of all three. Understanding why the eye is dry helps us choose treatments that address the underlying problem rather than simply adding moisture temporarily.
